GLP-1

News

Lilly says tirzepatide supply issues are resolving

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for startin

News

Novo Nordisk chief executive Lars Fruergaard Jørgensen

Wegovy slowdown rattles Novo Nordisk investors

Shares in Novo Nordisk have gone into reverse after it reported weaker-than-expected sales of obesity therapy Wegovy, raising concerns among investors about growing competition in the categ

News

Lilly gets first heart outcomes readout with tirzepatide

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefi

News

Conceptual image of cogs turning in the human brain

Older GLP-1 drug shows glimmer of benefit in Alzheimer's

It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists.

News

Innovent throws its hat further into China's GLP-1 ring

Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and E

News

Roche reveals first data with Carmot-sourced oral GLP-1 drug

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics as it tries to catch up with the leaders in the

Lilly says tirzepatide supply issues are resolving

Wegovy slowdown rattles Novo Nordisk investors

Lilly gets first heart outcomes readout with tirzepatide

Older GLP-1 drug shows glimmer of benefit in Alzheimer's

Innovent throws its hat further into China's GLP-1 ring

Roche reveals first data with Carmot-sourced oral GLP-1 drug

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

GLP-1

Editor's Picks